These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21160267)

  • 21. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
    Kiess AP; McArthur HL; Mahoney K; Patil S; Morris PG; Ho A; Hudis CA; McCormick B
    Cancer; 2012 Apr; 118(8):1982-8. PubMed ID: 21887681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
    Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
    Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Recurrent breast cancer to the sternum 15 years after radical mastectomy and primary lung cancer; report of a case].
    Tenpaku H; Maze Y; Sato T
    Kyobu Geka; 2004 Nov; 57(12):1165-7. PubMed ID: 15553040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
    Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
    J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Two cases of breast cancer responding to primary systemic chemotherapy containing trastuzumab without surgery].
    Konishi K; Hasegawa N; Kaneko H; Iimura Y; Shoji Y; Kawabata M
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):115-8. PubMed ID: 20087043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.
    Duraker N; Demir D; Bati B; Yilmaz BD; Bati Y; Çaynak ZC; Sobutay E
    Jpn J Clin Oncol; 2012 Jul; 42(7):601-8. PubMed ID: 22511807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Case report of advanced breast cancer responding to capecitabine and trastuzumab combination therapy].
    Yoshidome K; Imabun S; Nakahara M; Hiraoka K; Yamagami Y; Tsujimoto M; Nakao K
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1453-6. PubMed ID: 17033236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
    Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
    Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A case of breast meningeal carcinomatosis caused by trastuzumab treatment as adjuvant chemotherapy].
    Takahashi H; Fujii T; Inoue Y; Katsura M; Yokoyama G; Matsubayashi Namoto R; Nakayama Y; Momosaki S; Ariyama H; Takenaka M; Otsuka H; Iwakuma N; Toh U; Shirouzu K
    Gan To Kagaku Ryoho; 2010 Aug; 37(8):1607-9. PubMed ID: 20716898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effective combination chemotherapy using weekly trastuzumab and paclitaxel in the treatment of a recurrent breast cancer patient with liver metastases].
    Tohnosu N; Kobayashi Y; Saito T; Shimizu T; Natsume T; Tanaka H; Maruyama T; Watanabe Y
    Gan To Kagaku Ryoho; 2003 Jul; 30(7):989-92. PubMed ID: 12894716
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
    Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions.
    White RE; Vezeridis MP; Konstadoulakis M; Cole BF; Wanebo HJ; Bland KI
    J Am Coll Surg; 1996 Dec; 183(6):575-82. PubMed ID: 8957459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A case of 19th year pulmonary metastasis after radical mastectomy for breast cancer].
    Dohba S; Kondoh M; Fujita H; Kinami S; Inoue T; Komura Y; Ii T; Takegawa S; Kiriyama M; Kojima Y; Kibe Y; Watanabe K
    Kyobu Geka; 2000 Dec; 53(13):1129-32. PubMed ID: 11127561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isolate local failure after breast-conserving treatment for early breast cancer, about 57 cases.
    Deniaud-Alexandre E; Lauratet B; Lefranc JP; Genestié C; Lerouge D; Moureau-Zabotto L; Touboul E
    Cancer Radiother; 2004 Apr; 8(2):95-107. PubMed ID: 15063877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Liver arterial infusion chemotherapy with adjuvant trastuzumab for the simultaneous treatment of liver and breast cancer-a case report].
    Takahashi R; Fujii T; Inoue Y; Takahashi H; Akashi M; Nishida R; Takami Y; Saitsu H; Momosaki S; Nakayama Y; Uchino K; Takayoshi K; Shirouzu K
    Gan To Kagaku Ryoho; 2012 Nov; 39(11):1707-10. PubMed ID: 23152024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
    Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
    Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Breast-conservation treatment for early invasive breast cancer: prognostic factors for survival after salvage treatment of local recurrence].
    Fodor J
    Magy Onkol; 2007; 51(2):127-31. PubMed ID: 17660868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A case of multi-drug resistant recurrent breast cancer with multiple bone metastasis responding to TS-1 and trastuzumab].
    Nakajima H; Mizuta N; Mizuta M; Nakatsukasa K; Kobayashi A; Hachimine Y; Sakaguchi K; Fujiwara I; Sawai K
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1305-8. PubMed ID: 16969030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A case of recurrent breast cancer with lung metastasis and overexpression of HER2 that responded to UFT and cyclophosphamide combination therapy after sequential treatments with epirubicin, taxanes, and trastuzumab].
    Nishimura R; Nagao K; Miyayama H; Okazaki S; Nakagawa K; Fujimura Y
    Gan To Kagaku Ryoho; 2003 Jun; 30(6):879-82. PubMed ID: 12852361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.